재조합 단백질 시장 : 제품 및 서비스, 용도, 숙주세포, 최종 용도별 - 예측(2024-2032년)

The Recombinant Proteins Market revenue will grow at over 7.1% CAGR during 2024-2032, driven by the rising prevalence of chronic diseases. Physiopedia reports that approximately one-third of adults worldwide are impacted by multiple chronic conditions. Recombinant proteins play a crucial role in developing biopharmaceuticals and targeted therapies for treating these complex conditions. Their ability to mimic natural proteins and selectively target disease mechanisms makes them indispensable in the development of innovative treatments.

Moreover, advancements in genetic engineering and protein expression technologies enable more efficient and precise manipulation of genetic material to produce desired proteins. The focus on accelerating the development of new therapeutic and diagnostic products will bolster the market outlook in the coming years.

The recombinant proteins industry is classified based on products & services, host cell, end-use, and region.

The yeast & fungi host-cell segment will grow rapidly through 2032. These microorganisms offer advantages such as rapid growth rates, high protein expression yields, and post-translational modification capabilities that are crucial for producing biologically active proteins. Yeast-based systems, including Saccharomyces cerevisiae and Pichia pastoris, are widely used for industrial-scale production due to their robustness and compatibility with complex protein structures. Fungi like Aspergillus niger and Trichoderma reesei are also gaining traction, particularly in enzyme production and industrial biotechnology applications.

The diagnostics segment will grow at a steady pace through 2032, as recombinant proteins are essential in diagnostic assays for detecting diseases and monitoring patient health. They are used to produce antigens, antibodies, and enzymes critical for diagnostic tests such as enzyme-linked immunosorbent assays (ELISA), lateral flow assays, and molecular diagnostics. The specificity, sensitivity, and reproducibility of recombinant proteins make them ideal for developing accurate and reliable diagnostic tools. As the global healthcare industry emphasizes early disease detection and personalized medicine, the demand for recombinant proteins in diagnostics is expected to grow.

Europe recombinant proteins industry will witness decent growth trends during 2024 and 2032, characterized by a strong biopharmaceutical sector, extensive research infrastructure, and supportive regulatory framework. Countries like Germany, Switzerland, and the United Kingdom are leading hubs for biotechnology and pharmaceutical research, driving demand for recombinant proteins in drug discovery and development. Moreover, stringent quality standards and favorable reimbursement policies for biopharmaceutical products contribute to market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for biopharmaceuticals and therapeutic proteins
    • 3.2.1.2 Advancements in protein engineering
    • 3.2.1.3 Growing prevalence of chronic and infectious diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High production costs
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Cytokines & growth factors
    • 5.2.1.1 Interferons (IFNs)
    • 5.2.1.2 Interleukins (ILs)
    • 5.2.1.3 Other cytokines & growth factors
  • 5.2.2 Antibodies
  • 5.2.3 Immune checkpoint proteins
  • 5.2.4 Virus antigens
  • 5.2.5 Enzymes
    • 5.2.5.1 Kinases
    • 5.2.5.2 Metabolic enzymes
    • 5.2.5.3 Other enzymes
  • 5.2.6 Recombinant regulatory proteins
  • 5.2.7 Hormones
  • 5.2.8 Other products
• 5.3 Production services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery & development
  • 6.2.1 Biologics
  • 6.2.2 Vaccines
  • 6.2.3 Cell & gene therapies
• 6.3 Research
• 6.4 Diagnostics
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Host-cell, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Mammalian systems
• 7.3 Insect cells
• 7.4 Yeast & fungi
• 7.5 Bacterial cells
• 7.6 Other host-cells

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Academic & research institutes
• 8.4 Contract research organizations (CRO's)
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abcam Limited
• 10.2 Abnova Corporation
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 Enzo Life Sciences, Inc.
• 10.5 GenScript Biotech Corporation
• 10.6 Merck KGaA
• 10.7 Proteintech Group, Inc.
• 10.8 RayBiotech, Inc.
• 10.9 R&D Systems, Inc.
• 10.10 Sino Biological, Inc.
• 10.11 STEMCELL Technologies Inc.
• 10.12 Thermo Fisher Scientific Inc.